Analysts have been eager to weigh in on the Healthcare sector with new ratings on Edwards Lifesciences (NYSE:EW), Pfizer (NYSE:PFE) and Depomed (NASDAQ:DEPO).
Edwards Lifesciences (EW)
In a report released yesterday, Bruce Nudell from SunTrust Robinson reiterated a Buy rating on Edwards Lifesciences, with a price target of $170. The company’s shares closed yesterday at $139.15.
According to TipRanks.com, Nudell is a 4-star analyst with an average return of 9.5% and a 67.6% success rate. Nudell covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Merit Medical Systems, and Nuvectra Corporation.
Currently, the analyst consensus on Edwards Lifesciences is a Strong Buy with an average price target of $156.29, a 12.3% upside from current levels. In a report issued on July 27, Canaccord Genuity also maintained a Buy rating on the stock with a $177 price target.
.
See today’s analyst top recommended stocks >>
Pfizer (PFE)
SunTrust Robinson analyst John Boris reiterated a Hold rating on Pfizer yesterday and set a price target of $41. The company’s shares closed yesterday at $41, close to its 52-week high of $41.64.
According to TipRanks.com, Boris is a 4-star analyst with an average return of 10.8% and a 67.3% success rate. Boris covers the Healthcare sector, focusing on stocks such as Avadel Pharmaceuticals plc, Jazz Pharmaceuticals, and Merck & Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Pfizer with a $41.50 average price target, a 1.2% upside from current levels. In a report issued on July 31, Jefferies also maintained a Hold rating on the stock with a $39 price target.
.
Depomed (DEPO)
Mizuho Securities analyst Irina Rivkind Koffler reiterated a Buy rating on Depomed today and set a price target of $10. The company’s shares closed yesterday at $7.56.
According to TipRanks.com, Koffler is a 5-star analyst with an average return of 12.0% and a 48.9% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Pacira Pharmaceuticals.
Currently, the analyst consensus on Depomed is a Moderate Buy with an average price target of $8.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
